Congenital Abnormality
Australia Rejects Eisai’s Alzheimer’s Drug Leqembi
Leqembi, Eisai, Alzheimer’s disease, Australia, TGA, drug rejection
Regeneron gene therapy improves hearing in 10 children with rare form of hearing loss
Regeneron Pharmaceuticals, DB-OTO gene therapy, otoferlin (OTOF) gene, congenital hearing loss, intracochlear injection
Emerging Competitors in Achondroplasia Treatment: BioMarin’s Dominance Faces New Challenges
Achondroplasia, BioMarin, Voxzogo, BridgeBio, infigratinib, TransCon CNP, RBM-007, skeletal disorders, dwarfism, genetic bone disorders.
Healthcare Sector Winners and Losers in the 2024 Government Funding Bill
Healthcare funding, government shutdown, telehealth, Medicare payments, Medicaid DSH, hospital-at-home programs, physician pay cuts, healthcare legislation.
Philips and AWS Strengthen Strategic AI Partnership, Expanding Cloud-Enabled Diagnostics to Europe
Philips, AWS, Strategic AI Collaboration, Cloud-Enabled Diagnostics, European Expansion, Healthcare Innovation, Integrated Diagnostics Portfolio, Generative AI Applications
Sanofi Invests €300M in Orano Med for Next-Generation Radioligand Therapies
Sanofi, Orano Med, Radioligand Therapies, Rare Cancers, AlphaMedix, Lead-212 (212Pb), Targeted Alpha Therapies
Ascendis Challenges BioMarin’s Dominance with Promising Achondroplasia Drug Data
Achondroplasia, Ascendis Pharma, BioMarin, TransCon CNP, VOXZOGO, Dwarfism Treatment
Sanofi Enters Radiopharmaceutical Market with $110 Million Licensing Agreement
Sanofi, Radiopharmaceuticals, Licensing Deal, RadioMedix, Orano Med, AlphaMedix, Neuroendocrine Tumors
Recursion’s Phase 2 Trial for Cerebral Cavernous Malformation Shows Limited Efficacy Despite Meeting Safety Goals
Recursion Pharmaceuticals, Phase 2 trial, cerebral cavernous malformation (CCM), REC-994, safety and tolerability, efficacy data, FDA meeting
FDA Approves Revolutionary Re-Expandable Stent for Young Children
FDA approval, re-expandable stent, young children, congenital heart disease, minimally invasive procedures